Division of HiFiBio Therapeutics
Latest From HiFiBiO Therapeutics
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in August and September.
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- HiFiBio Therapeutics
- HiFiBiO Therapeutics
- Senior Management
Liang Schweizer, PhD, CEO & CSO
Fred Dom, CFO
Jeff He, COO
- Contact Info
237 Putnam Ave.
Cambridge, MA 02139
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.